• Home
  • Autotelic Bio
6-8
Oct
2026
CPHI Milan 2026
Fiera Milano, Italy
2C54
Book a meeting

Autotelic Bio

About Autotelic Bio

Autotelic Bio, under the vision of becoming the global leader of cancer treatments, researches and develops innovative new drugs, with a sense of duty to improve the quality of life for unmet medical needs around the world. Autotelic Bio took its first step in 2015 with 15 to 20 years of experienced board members in each filed of pharmaceutical industry such as global business development, R&D, clinical study, etc.


  • ATB-301 [TGF-β2 Targeting ASO (TASO) + IL-2 Combination therapy] - Phase Ib

Key Features

1. Confirm the potential of TGF-β2 as a biomarker in human blood and tumor tissues from the efficacy ...

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less

Meet us at

  • CPHI Milan 2026

    CPHI Milan 2026

    Fiera Milano, Italy
    6 Oct 2026 - 8 Oct 2026
  • Country/Region:
    Korea, Republic Of
  • On CPHI since:
    2021
  • Employees:
    25 - 49
Company types
Manufacturer/Innovator
Contact info
  • +827042863041
  • Website
  • #302, 194-41, Osong-saengmyeong 1-ro, Osong-eup, Chungcheongbuk-do, 28610, Heungdeok-gu, Cheongju-si, Korea, Republic Of
Show contact info Hide contact info

Products from Autotelic Bio (4)

  • ATB-330

    Product ATB-330

    [ALK5 inhibitor / Small Molecule / Develop for IPF and Fibrosis) – Complete to derivate the lead compound

    1. Confirm the highest ALK5 selectivity with superior efficacy and PK profile through in-vivo tests compared to competitors (small molecule new drugs) 
    ...
  • ATB-101

    Product ATB-101

    [ARB+SGLT-2i Fixed Dose Combination] – In process of Phase 3 clinical trial on approx. 250 patients
    1. The first Fixed Dose Combination treating hypertension and type 2 diabetes by a tablet in the world

    2. Expect the synergistic effect in the treatment of hypertension though mi...
  • ATB-301

    Product ATB-301

    [TGF-β2 Targeting ASO (TASO) + IL-2 Combination therapy] - Phase Ib

    1. Confirm the potential of TGF-β2 as a biomarker in human blood and tumor tissues from the efficacy result of Phase Ib clinical trial on cancer patients 

    2. Confirm the suppression of IL-2’s side effect in combinati...
  • ATB-320

    Product ATB-320

    [Immune Targeting Dual MOA anti-cancer agent] – Pre-clinical toxicology, TK, and safety pharmacology studies are ongoing and expect to be approved for Phase I IND by US FDA in 1st quarter of 2023

    1. Confirmation of the synergistic effect of combination therapy with PD-1 & cyto...

Autotelic Bio Resources (1)